Vir Biotechnology, Inc. Form 8-K (May 20, 2020)

Summary

Form 8-K for an event dated May 20, 2020, filed by Vir Biotechnology, Inc. Under Item 5.07, the report states that stockholders at the 2020 Annual Meeting of Stockholders on May 20, 2020 elected Kristina Burow, Robert More and Vicki Sato, Ph.D. as Class I Directors, each to serve until the 2023 Annual Meeting. Votes for Kristina Burow were 62,514,147, with 363,745 withheld. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2020, with 63,862,989 for, 28,183 against and 27,418 abstentions. Howard Horn, Chief Financial Officer, signed with the date May 22, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

8-K 1 d931707d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT
REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 20, 2020

Vir Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware | 001-39083 | 81-2730369
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)
499 Illinois Street, Suite 500 San Francisco, California | 94158
(Address of principal executive offices) | (Zip Code)

Registrant’s telephone number, including area code: (415) 906-4324

Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which
registered
Common Stock, $0.0001 par value per share | VIR | Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 | Submission of Matters to a Vote of Security Holders.

On May 20, 2020, Vir Biotechnology, Inc. (the “Company”) held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”). As
of March 27, 2020, the record date for the Annual Meeting, 109,803,505 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth
below.

Proposal 1. Election of Directors

The
Company’s stockholders elected the three persons listed below as Class I Directors, each to serve until the Company’s 2023 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final
voting results are as follows:

Votes For | Votes Withheld | Broker Non-Votes
Kristina Burow | 62,514,147 | 363,745 | 1,040,698
Robert More | 62,754,101 | 123,791 | 1,040,698
Vicki Sato, Ph.D. | 62,606,467 | 271,425 | 1,040,698

Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the
Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020. The final voting results are as follows:

Votes For | Votes Against | Abstentions | Broker Non-Votes
63,862,989 | 28,183 | 27,418 | 0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.

Vir Biotechnology, Inc.
Dated: May 22, 2020 | By: | /s/ Howard Horn
Howard Horn
Chief Financial Officer

File and source

File

SEC_VIR_8-K_filed2020-05-22_0001193125-20-150065.htm

Size

21,726 bytes

SHA-256

be18e67a2ff58799354959b2619e871178d568003f7be957b144c8d2943f8db7

Our copy

SEC_VIR_8-K_filed2020-05-22_0001193125-20-150065.htm

Original

www.sec.gov